Cargando…
The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL
Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic leukemia (ALL) have improved significantly in the past few decades. Treatment advances have provided 5-year survival rates ranging from 78 to 91% depending on the age at diagnosis. However, approximately 2–3% of patien...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342933/ https://www.ncbi.nlm.nih.gov/pubmed/30670684 http://dx.doi.org/10.1038/s41408-018-0164-6 |